ADx NeuroSciences NV enters into exclusive license agreement with K.U.Leuven for the development of antibodies used in dementia diagnosis
ADx NeuroSciences NV entered into a license agreement with K.U.Leuven, the academic founder of ADx NeuroSciences. The license agreement grants ADx NeuroSciences exclusive worldwide rights to further develop and commercialise certain antibodies which selectively bind phosphorylated Tau aggregates. ADx NeuroSciences is a new biotech company that focuses on the development of novel (bio)markers for use in the diagnosis of dementia, such as Alzheimer’s, Parkinson’s and other neurodegenerative diseases.
Current tests to diagnose patients with Alzheimer’s disease are unable to indicate the prognosis of the disease. As a consequence, the pharma industry as well as clinicians will urgently need novel markers to be able to identify patients and to predict how the disease evolves. In response to this demand, ADx NeuroSciences aims to commercialise diagnostic products for neurodegenerative disorders that are developed in close collaboration with pharma.
”This license agreement is an important step for the development of ADx NeuroSciences to further create value as well as in the establishment of a solid and long-term relationship and alliance with K.U.Leuven”, says Koen Dewaele, CEO of ADx NeuroSciences.
“We are pleased to support ADx NeuroSciences by providing it with a strong intellectual property position”, says Prof. Joris Winderickx, chair of the Leuven Bio-Science, Bio-Engineering and Bio-Technology Centre, K.U.Leuven. “This license agreement puts ADx NeuroSciences in pole position to unravel the role of Tau pathology – Tau is a hallmark in the AD process – in the diagnosis of Alzheimer’s disease.”
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Rockeby awarded bird flu tests tender from Middle East
Rentschler focuses on biotechnology

How cancer genes become independent - Study sheds light on the mysterious evolution of DNA rings

Blueprint of Oxytocin Receptor Facilitates Development of New Autism Drugs
Merck and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer
Provence Technologies and Neuroptis Biotech partner to develop a new compound for treating dry eye syndrome
Mayo researchers develop new laboratory cell lines to study treatment for ATC
Diabetes advance: Researchers find gene that causes resistance to insulin - Discovery is first gene known to affect how insulin works, not how it is produced

ZEISS Ventures invests in life science start-up InSphero to drive 3D cell culture research - Strategic investment is closely linked to ZEISS Research Microscopy Solutions and its capabilities in automated, high-resolution imaging and 3D image analysis

Culture Biosciences Raises $80M Series B to Tackle Demand for Large-Scale Biomanufacturing - Culture is closing the gap in manufacturing capacity with its large-scale cloud bioreactors
Mechanical heart valve prosthesis superior to biological
